Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

Pallawi Torka, Shalin K. Kothari, Suchitra Sundaram, Shaoying Li, L. Jeffrey Medeiros, Emily C. Ayers, Daniel J. Landsburg, David A. Bond, Kami J. Maddocks, Anshu Giri, Brian Hess, Luu Q. Pham, Ranjana Advani, Yang Liu, Stefan Klaus Barta, Julie M. Vose, Michael C. Churnetski, Jonathon B. Cohen, Madelyn Burkart, Reem KarmaliJoanna Zurko, Amitkumar Mehta, Adam J. Olszewski, Sarah Lee, Brian T. Hill, Timothy F. Burns, Frederick Lansigan, Emma Rabinovich, David Peace, Adrienne Groman, Kristopher Attwood, Francisco J. Hernandez-Ilizaliturri

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


There is a paucity of data regarding outcomes and response to standard therapy in patients with limited-stage (LS) agressive B-cell lymphoma (LS-ABCL) who harbor MYC rearrangement (MYC-R) with or without BCL2 and/or BCL6 rearrangements. We conducted a multicenter retrospective study of MYC-R LS-ABCL patients who received either rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), or more intensive immunochemotherapy (IIC) plus or minus consolidative involved-field radiation therapy (IFRT). One hundred four patients from 15 academic centers were included. Forty four patients (42%) received R-CHOP, of whom 52% had IFRT. Sixty patients (58%) received IIC, of whom 40% had IFRT. Overall response rate was 91% (84% complete response [CR]; 7% partial response). Patients with double-hit lymphoma (DHL; n = 40) had a lower CR rate compared with patients with MYC-R only (75% vs 98%; P = .003). CR rate was higher in the IFRT vs no-IFRT group (98% vs 72%; P<.001). Median follow-up was 3.2 years; 2-year progression-free survival (PFS) and overal survival (OS) were 78% and 86% for the entire cohort, and 74% and 81% for the DHL patients, respectively. PFS and OS were similar across treatment groups (IFRT vs no IFRT, R-CHOP vs IIC) in the entire cohort and in DHL patients. Our data provide a historical benchmark for MYC-R LS-ABCL and LS-DHL patients and show that outcomes for this population may be better than previously recognized. There was no benefit of using IIC over R-CHOP in patients with MYC-R LS-ABCL and LS-DHL.

Original languageEnglish (US)
Pages (from-to)253-262
Number of pages10
JournalBlood Advances
Issue number2
StatePublished - Jan 28 2020

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics'. Together they form a unique fingerprint.

Cite this